Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 37 min ago
Peer-reviewedCC BY-NC-ND 4.0In Vivo

Dose-dependent Effects of Botulinum Toxin Type E in the Mouse Digit Abduction Score Model

  • ZHIYUAN DING1,2
  • CAIJUN JIN1,2
  • JAE YOUNG KIM3
  • JEONG SUN NAM3
  • YOON KYOUNG CHA3
  • YOUNG GILL BYEOUN3
  • JAE HYUN JEONG3
  • CHUL MIN NA3
  • YONG HYUN LEE4
  • PHAM NGOC CHIEN2
  • CHAN YEONG HEO1,2,4
4 affiliations
  1. 1Department of Plastic and Reconstructive Surgery, Seoul National University, College of Medicine, Seoul, Republic of Korea
  2. 2Department of Plastic and Reconstructive Surgery, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
  3. 3Jetema Co. Ltd, R&D Center, Yongin-si, Republic of Korea
  4. 4Korean Institute of Nonclinical Study, H&Bio. Co. Ltd., Seongnam, Republic of Korea
Read full textPDFDOICite

Abstract

Background/Aim: Botulinum Toxin Type A (BOTOX®) is widely used, but its long duration may be unsuitable when a rapid and short-lasting effect is desired. This study aimed to evaluate the dose-dependent effects of botulinum toxin type E (JTM204) in the mouse digit abduction score model and compare its onset and duration with BOTOX®.

Materials and Methods: Female Institute of Cancer Research (ICR) mice received intramuscular injections of JTM204 at doses of 18.2, 28.9, 45.5, 72.2, 115.0, or 182.0 U/kg into the right gastrocnemius muscle. Mouse digit abduction score (DAS) responses were scored using a 0-4 scale at multiple time points from 3 to 72 h post-injection. Peak response, duration of effect, and dose dependency were assessed. The highest JTM204 dose was compared with contemporaneously evaluated BOTOX® data at 24.3 U/kg.

Results: JTM204 produced a rapid, dose-dependent inhibition of digit abduction. Detectable activity was observed by 3 h, with peak effects occurring between 12 and 24 h. The highest dose produced the strongest response, reaching a mean peak DAS of approximately 3.6. DAS values declined markedly by 48 h and returned to baseline by 72 h in all dose groups. Compared with BOTOX®, JTM204 showed a faster onset and much shorter duration, while Botulinum Toxin Type A peaked later and persisted for up to 14 days.

Conclusion: JTM204 demonstrated rapid-onset, dose-dependent, and fully reversible muscle-weakening activity, supporting its potential as a short-acting botulinum toxin for applications requiring temporary neuromuscular blockade.

Related

  1. The motor endplate band as an optimal target for botulinum toxin in congenital torticollis: evidence from a rabbit model
    Ren Chen, Ji Zhang, Rurong Duan +2
    Translational pediatricsPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  2. Botulinum toxin type A for subacute/chronic neck pain
    Anita R Gross, Haejung Lee, Nejin Chacko +8
    The Cochrane Database of Systematic ReviewsPeer-reviewedPublisher termsFull text2 citedNeurologyPMC
  3. Notes from the Field: Investigation of Unapproved Botulinum Toxin Product Administered at a Medical Spa - Colorado, 2025-2026.
    Pallavi Oruganti, Natalia G Riemer, Cayla E Mayle +11
    MMWR. Morbidity and mortality weekly reportPeer-reviewedLicence not statedFull textNeurologyEurope PMC
  4. Perioperative Anesthesia: Botulinum Toxin Injection in a 6‐Year‐Old Female With “No Burp Disease”
    Logan D. Applewhite, Lawrence D. Garcia-Reyes, Paul M. Weinberger
    Case Reports in AnesthesiologyPeer-reviewedCC BY 4.0Full textSurgery & anaesthesiaPMC
  5. Muscle- and Gland-Specific Dosing of Botulinum Toxin in Facial Aesthetics: Review of Dose Ranges, Target Depth, Muscle Thickness, and Neuromuscular or Glandular Anatomy.
    Kyu-Ho Yi, Kyu-Lim Lee
    ToxinsPeer-reviewedCC BYFull textNeurologyEurope PMC

Cite

BibTeXRIS
BibTeX
@article{ding2026dosedependent,
  title = {{Dose-dependent Effects of Botulinum Toxin Type E in the Mouse Digit Abduction Score Model}},
  author = {ZHIYUAN DING and CAIJUN JIN and JAE YOUNG KIM and JEONG SUN NAM and YOON KYOUNG CHA and YOUNG GILL BYEOUN and JAE HYUN JEONG and CHUL MIN NA and YONG HYUN LEE and PHAM NGOC CHIEN and CHAN YEONG HEO},
  journal = {In Vivo},
  year = {2026},
  month = oct,
  doi = {10.21873/invivo.14490},
  url = {https://doi.org/10.21873/invivo.14490},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Dose-dependent Effects of Botulinum Toxin Type E in the Mouse Digit Abduction Score Model
AU  - ZHIYUAN DING
AU  - CAIJUN JIN
AU  - JAE YOUNG KIM
AU  - JEONG SUN NAM
AU  - YOON KYOUNG CHA
AU  - YOUNG GILL BYEOUN
AU  - JAE HYUN JEONG
AU  - CHUL MIN NA
AU  - YONG HYUN LEE
AU  - PHAM NGOC CHIEN
AU  - CHAN YEONG HEO
PY  - 2026
DA  - 2026/10/29
JO  - In Vivo
DO  - 10.21873/invivo.14490
UR  - https://doi.org/10.21873/invivo.14490
AB  - Background/Aim: Botulinum Toxin Type A (BOTOX®) is widely used, but its long duration may be unsuitable when a rapid and short-lasting effect is desired. This study aimed to evaluate the dose-dependent effects of botulinum toxin type E (JTM204) in the mouse digit abduction score model and compare its onset and duration with BOTOX®.  Materials and Methods: Female Institute of Cancer Research (ICR) mice received intramuscular injections of JTM204 at doses of 18.2, 28.9, 45.5, 72.2, 115.0, or 182.0 U/kg into the right gastrocnemius muscle. Mouse digit abduction score (DAS) responses were scored using a 0-4 scale at multiple time points from 3 to 72 h post-injection. Peak response, duration of effect, and dose dependency were assessed. The highest JTM204 dose was compared with contemporaneously evaluated BOTOX® data at 24.3 U/kg.  Results: JTM204 produced a rapid, dose-dependent inhibition of digit abduction. Detectable activity was observed by 3 h, with peak effects occurring between 12 and 24 h. The highest dose produced the strongest response, reaching a mean peak DAS of approximately 3.6. DAS values declined markedly by 48 h and returned to baseline by 72 h in all dose groups. Compared with BOTOX®, JTM204 showed a faster onset and much shorter duration, while Botulinum Toxin Type A peaked later and persisted for up to 14 days.  Conclusion: JTM204 demonstrated rapid-onset, dose-dependent, and fully reversible muscle-weakening activity, supporting its potential as a short-acting botulinum toxin for applications requiring temporary neuromuscular blockade.
SN  - 0258-851X
SN  - 1791-7549
ER  -